Ebola Clinical Trial
Official title:
A Phase I Study to Determine the Safety and Immunogenicity of a Bivalent ChAdOx1 Vectored Vaccine Against Zaire and Sudan Ebola Virus Species in UK Healthy Adult Volunteers
An open-label, non-randomised, dose escalation, first-in-human, single centre, phase I clinical trial to determine the safety and immunogenicity of a bivalent ChAdOx1 vectored vaccine against Zaire and Sudan Ebola virus species in healthy adult volunteers.
This is a first-in-human, open-label, dose escalation, phase I clinical trial to assess the safety and immunogenicity of the candidate ChAdOx1 biEBOV vaccine in healthy UK volunteers aged 18-55. The vaccine will be administered intramuscularly (IM). Volunteers will be recruited and vaccinated at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford. There will be 3 study groups and it is anticipated that a total of 26 volunteers will be enrolled. Dose escalation and sentinel participant procedures will be implemented. Volunteers will be first recruited into Group 1 and subsequently into Groups 2 and 3 following interim clinical safety reviews. Volunteers will be sequentially allocated to a study group by selecting eligible volunteers for enrolment following screening. Sequential allocation will occur based on the order in which volunteers are enrolled. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05284097 -
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
|
Phase 2 | |
| Completed |
NCT02240875 -
A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
|
Phase 1 | |
| Completed |
NCT05064956 -
Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)
|
Phase 2 | |
| Completed |
NCT04385719 -
Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy
|
Phase 2 | |
| Active, not recruiting |
NCT05301504 -
A Study in Tanzania of a New Vaccine Against Two Types of Ebola
|
Phase 1 | |
| Completed |
NCT00646152 -
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
|
Phase 1 | |
| Completed |
NCT02818582 -
GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
|
Phase 2 | |
| Completed |
NCT02370589 -
Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04228783 -
A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
|
Phase 3 | |
| Active, not recruiting |
NCT03031912 -
African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
|
Phase 2 |